JP2018519797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519797A5 JP2018519797A5 JP2017557175A JP2017557175A JP2018519797A5 JP 2018519797 A5 JP2018519797 A5 JP 2018519797A5 JP 2017557175 A JP2017557175 A JP 2017557175A JP 2017557175 A JP2017557175 A JP 2017557175A JP 2018519797 A5 JP2018519797 A5 JP 2018519797A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- dsrna agent
- seq
- pharmaceutical composition
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 52
- 239000002773 nucleotide Substances 0.000 claims 44
- 239000003795 chemical substances by application Substances 0.000 claims 41
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 230000000692 anti-sense effect Effects 0.000 claims 11
- 206010019860 Hereditary angioedema Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 108091081021 Sense strand Proteins 0.000 claims 9
- 108010080865 Factor XII Proteins 0.000 claims 8
- 102000000429 Factor XII Human genes 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 7
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 230000037361 pathway Effects 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 101150072419 F12 gene Proteins 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000009467 reduction Effects 0.000 claims 3
- 229920002477 rna polymer Polymers 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- MPCAJMNYNOGXPB-UHFFFAOYSA-N 1,5-anhydrohexitol Chemical compound OCC1OCC(O)C(O)C1O MPCAJMNYNOGXPB-UHFFFAOYSA-N 0.000 claims 2
- 208000028185 Angioedema Diseases 0.000 claims 2
- 101800004538 Bradykinin Proteins 0.000 claims 2
- 208000007530 Essential hypertension Diseases 0.000 claims 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 2
- 102100035792 Kininogen-1 Human genes 0.000 claims 2
- 108700018490 Prekallikrein Deficiency Proteins 0.000 claims 2
- 230000008901 benefit Effects 0.000 claims 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 2
- ZDPUTNZENXVHJC-UHFFFAOYSA-N cumingianoside D Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(OP(O)(O)=O)C1O ZDPUTNZENXVHJC-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 230000002885 thrombogenetic effect Effects 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- KBDWGFZSICOZSJ-UHFFFAOYSA-N 5-methyl-2,3-dihydro-1H-pyrimidin-4-one Chemical group N1CNC=C(C1=O)C KBDWGFZSICOZSJ-UHFFFAOYSA-N 0.000 claims 1
- UOOOPKANIPLQPU-UHFFFAOYSA-N Cytidylic acid B Natural products O=C1N=C(N)C=CN1C1C(O)C(OP(O)(O)=O)C(CO)O1 UOOOPKANIPLQPU-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical class CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- NPRNBAPBGVERRF-ZOQUXTDFSA-N [(2r,3r,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl] dihydrogen phosphate Chemical compound CO[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 NPRNBAPBGVERRF-ZOQUXTDFSA-N 0.000 claims 1
- VXTNWQOOBHQEDS-IOSLPCCCSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl] dihydrogen phosphate Chemical compound CO[C@@H]1[C@H](OP(O)(O)=O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VXTNWQOOBHQEDS-IOSLPCCCSA-N 0.000 claims 1
- PTESHFKYBQMNFR-FJGDRVTGSA-N [(2r,3r,4s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@](F)(O)[C@H](OP(O)(O)=O)[C@@H](CO)O1 PTESHFKYBQMNFR-FJGDRVTGSA-N 0.000 claims 1
- KLVQSNKMLGBSHV-GIWSHQQXSA-N [(2r,3r,4s,5r)-5-(6-aminopurin-9-yl)-4-fluoro-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@]1(O)F KLVQSNKMLGBSHV-GIWSHQQXSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020075777A JP7530204B2 (ja) | 2015-05-06 | 2020-04-22 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562157890P | 2015-05-06 | 2015-05-06 | |
| US62/157,890 | 2015-05-06 | ||
| US201562260887P | 2015-11-30 | 2015-11-30 | |
| US62/260,887 | 2015-11-30 | ||
| US201562266958P | 2015-12-14 | 2015-12-14 | |
| US62/266,958 | 2015-12-14 | ||
| PCT/US2016/030876 WO2016179342A2 (en) | 2015-05-06 | 2016-05-05 | Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020075777A Division JP7530204B2 (ja) | 2015-05-06 | 2020-04-22 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519797A JP2018519797A (ja) | 2018-07-26 |
| JP2018519797A5 true JP2018519797A5 (enExample) | 2019-06-06 |
| JP6695902B2 JP6695902B2 (ja) | 2020-05-20 |
Family
ID=55971215
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557175A Active JP6695902B2 (ja) | 2015-05-06 | 2016-05-05 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| JP2020075777A Active JP7530204B2 (ja) | 2015-05-06 | 2020-04-22 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| JP2022106599A Pending JP2022141707A (ja) | 2015-05-06 | 2022-06-30 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020075777A Active JP7530204B2 (ja) | 2015-05-06 | 2020-04-22 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
| JP2022106599A Pending JP2022141707A (ja) | 2015-05-06 | 2022-06-30 | 第ＸＩＩ因子（ハーゲマン因子）（Ｆ１２）、カリクレインＢ、血漿（フレッチャー因子）１（ＫＬＫＢ１）、及びキニノーゲン１（ＫＮＧ１）ｉＲＮＡ組成物及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20180100150A1 (enExample) |
| EP (1) | EP3292201A2 (enExample) |
| JP (3) | JP6695902B2 (enExample) |
| KR (2) | KR20250107273A (enExample) |
| CN (2) | CN115322991A (enExample) |
| AU (3) | AU2016257996A1 (enExample) |
| BR (1) | BR112017021967A2 (enExample) |
| CA (1) | CA2984636A1 (enExample) |
| EA (1) | EA201792444A1 (enExample) |
| HK (1) | HK1249920A1 (enExample) |
| TW (4) | TWI887656B (enExample) |
| UY (2) | UY40330A (enExample) |
| WO (1) | WO2016179342A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016149331A2 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Compositions and methods for inhibiting gene expression of factor xii |
| CN115322991A (zh) | 2015-05-06 | 2022-11-11 | 阿尔尼拉姆医药品有限公司 | 因子XII、激肽释放酶B、血浆夫列契因子1和激肽原1 iRNA组合物及其使用方法 |
| US10883107B2 (en) | 2016-01-08 | 2021-01-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof |
| EP3573623A4 (en) | 2017-01-30 | 2020-11-25 | Arrowhead Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS OF INHIBITION OF GENE EXPRESSION OF FACTOR XII |
| SG11201909433XA (en) * | 2017-04-11 | 2019-11-28 | Arbutus Biopharma Corp | Targeted compositions |
| EP3649243A1 (en) * | 2017-07-07 | 2020-05-13 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12) |
| WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105437A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105414A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105418A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| KR102617947B1 (ko) | 2017-12-29 | 2023-12-27 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 접합체와 제조 및 그 용도 |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| WO2020063198A1 (zh) | 2018-09-30 | 2020-04-02 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| EP3903830A4 (en) | 2018-12-28 | 2023-04-26 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE |
| CN118562796A (zh) * | 2019-01-18 | 2024-08-30 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN113811613B (zh) * | 2019-05-22 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| AU2020280438B2 (en) | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| EP3992290A4 (en) * | 2019-05-24 | 2023-11-15 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
| AU2021216451A1 (en) | 2020-02-07 | 2022-09-29 | Intellia Therapeutics, Inc. | Compositions and methods for kallikrein ( KLKB1) gene editing |
| WO2021195574A1 (en) * | 2020-03-27 | 2021-09-30 | Alnylam Pharmaceuticals, Inc. | Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| US12018261B2 (en) | 2020-12-18 | 2024-06-25 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating factor XII |
| MX2024001573A (es) | 2021-08-13 | 2024-02-14 | Alnylam Pharmaceuticals Inc | Composiciones de acido ribonucleico de interferencia (arni) contra el factor xii (f12) y sus metodos de uso. |
| TW202346586A (zh) * | 2022-01-28 | 2023-12-01 | 大陸商上海舶望製藥有限公司 | 用於抑制前激肽釋放酶（pkk）蛋白表達的組合物和方法 |
| WO2024169577A1 (zh) * | 2023-02-14 | 2024-08-22 | 北京福元医药股份有限公司 | 用于抑制fxii基因表达的双链核糖核酸及其修饰物、缀合物和用途 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1861608A (en) | 1929-12-21 | 1932-06-07 | Emerson Electric Mfg Co | Fan and means for directing the air current therethrough |
| US1861108A (en) | 1930-01-24 | 1932-05-31 | Eugene O Brace | Integral clutch and transmission control |
| US3974808A (en) | 1975-07-02 | 1976-08-17 | Ford Motor Company | Air intake duct assembly |
| US4708708A (en) | 1982-12-06 | 1987-11-24 | International Paper Company | Method and apparatus for skiving and hemming |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| NL8901881A (nl) | 1989-07-20 | 1991-02-18 | Rockwool Grodan Bv | Drainagekoppelelement. |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| AU4528493A (en) | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
| WO1994000569A1 (en) | 1992-06-18 | 1994-01-06 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| US5783701A (en) | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| WO1994018987A1 (fr) | 1993-02-19 | 1994-09-01 | Nippon Shinyaku Co., Ltd. | Composition medicinale renfermant un copolymere d'acide nucleique |
| US6054299A (en) | 1994-04-29 | 2000-04-25 | Conrad; Charles A. | Stem-loop cloning vector and method |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| EP0832271B8 (en) | 1995-06-07 | 2005-03-02 | INEX Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
| US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
| US6034135A (en) | 1997-03-06 | 2000-03-07 | Promega Biosciences, Inc. | Dimeric cationic lipids |
| CA2316218A1 (en) | 1997-12-24 | 1999-07-08 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
| US6436989B1 (en) | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| ATE237312T1 (de) | 1998-07-20 | 2003-05-15 | Protiva Biotherapeutics Inc | In liposomen verkapselte nukleinsäurekomplexe |
| BR9914773A (pt) | 1998-10-09 | 2002-02-05 | Ingene Inc | Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica |
| JP2002527061A (ja) | 1998-10-09 | 2002-08-27 | インジーン・インコーポレイテッド | ｓｓＤＮＡの酵素的合成 |
| CO5261510A1 (es) | 1999-02-12 | 2003-03-31 | Vertex Pharma | Inhibidores de aspartil proteasa |
| IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| PT2070939E (pt) * | 2001-05-25 | 2014-06-09 | Univ Duke | Moduladores de agentes farmacológicos |
| AU2002323151A1 (en) | 2001-08-13 | 2003-03-03 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| CN101052717A (zh) | 2004-05-11 | 2007-10-10 | α基因株式会社 | 诱发rna干扰的多核苷酸以及使用该多核苷酸的基因表达抑制方法 |
| EP1802644B1 (en) * | 2004-09-24 | 2012-11-07 | Alnylam Pharmaceuticals Inc. | Rnai modulation of apob and uses thereof |
| EP1954822A1 (en) * | 2005-11-23 | 2008-08-13 | Georg Dewald | Detection and treatment of drug associated angioedema |
| US8178503B2 (en) * | 2006-03-03 | 2012-05-15 | International Business Machines Corporation | Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes |
| WO2007130604A2 (en) * | 2006-05-04 | 2007-11-15 | Baylor Research Institute | Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna |
| EP2423307A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IV polypeptides and use thereof for treatment |
| AU2007275365A1 (en) * | 2006-07-17 | 2008-01-24 | Sirna Therapeutics Inc. | RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA) |
| EP2215256A1 (en) * | 2007-10-22 | 2010-08-11 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| MX2011004909A (es) * | 2008-11-17 | 2011-05-30 | Hoffmann La Roche | Composiciones y metodos para inhibir la expresion de genes del factor vii. |
| PL3431076T3 (pl) | 2009-06-10 | 2022-01-31 | Arbutus Biopharma Corporation | Ulepszona formulacja lipidowa |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| WO2011005861A1 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
| US9150864B2 (en) * | 2010-11-08 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| KR102232287B1 (ko) * | 2011-06-21 | 2021-03-29 | 알닐람 파마슈티칼스 인코포레이티드 | 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법 |
| IN2014CN03465A (enExample) | 2011-11-18 | 2015-10-09 | Alnylam Pharmaceuticals Inc | |
| CN102600471A (zh) * | 2012-02-15 | 2012-07-25 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种败血症治疗的靶点 |
| US9574013B2 (en) * | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
| EP2951305B1 (en) | 2013-01-30 | 2018-08-15 | F.Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| SG10201700239UA (en) * | 2013-03-14 | 2017-02-27 | Alnylam Pharmaceuticals Inc | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| UY40064A (es) * | 2013-05-22 | 2023-02-28 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO |
| SG10202103166XA (en) * | 2013-05-22 | 2021-04-29 | Alnylam Pharmaceuticals Inc | Tmprss6 irna compositions and methods of use thereof |
| WO2016149020A1 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Rna interference agents |
| WO2016149331A2 (en) | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Compositions and methods for inhibiting gene expression of factor xii |
| CN115322991A (zh) | 2015-05-06 | 2022-11-11 | 阿尔尼拉姆医药品有限公司 | 因子XII、激肽释放酶B、血浆夫列契因子1和激肽原1 iRNA组合物及其使用方法 |
| US10883107B2 (en) | 2016-01-08 | 2021-01-05 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof |
| CN117757791A (zh) | 2016-11-23 | 2024-03-26 | 阿尔尼拉姆医药品有限公司 | 具有降低的脱靶效应的修饰的rna试剂 |
| EP3573623A4 (en) | 2017-01-30 | 2020-11-25 | Arrowhead Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS OF INHIBITION OF GENE EXPRESSION OF FACTOR XII |
| EP3649243A1 (en) | 2017-07-07 | 2020-05-13 | Alnylam Pharmaceuticals, Inc. | Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12) |
| MX2024001573A (es) | 2021-08-13 | 2024-02-14 | Alnylam Pharmaceuticals Inc | Composiciones de acido ribonucleico de interferencia (arni) contra el factor xii (f12) y sus metodos de uso. |
-
2016
- 2016-05-05 CN CN202210790912.8A patent/CN115322991A/zh active Pending
- 2016-05-05 TW TW112118563A patent/TWI887656B/zh active
- 2016-05-05 EA EA201792444A patent/EA201792444A1/ru unknown
- 2016-05-05 WO PCT/US2016/030876 patent/WO2016179342A2/en not_active Ceased
- 2016-05-05 JP JP2017557175A patent/JP6695902B2/ja active Active
- 2016-05-05 KR KR1020257020838A patent/KR20250107273A/ko active Pending
- 2016-05-05 TW TW105113928A patent/TWI727948B/zh active
- 2016-05-05 EP EP16723004.4A patent/EP3292201A2/en active Pending
- 2016-05-05 TW TW110113584A patent/TWI806034B/zh active
- 2016-05-05 CN CN201680039784.6A patent/CN108271386B/zh active Active
- 2016-05-05 CA CA2984636A patent/CA2984636A1/en active Pending
- 2016-05-05 KR KR1020177033031A patent/KR102827366B1/ko active Active
- 2016-05-05 BR BR112017021967A patent/BR112017021967A2/pt not_active Application Discontinuation
- 2016-05-05 AU AU2016257996A patent/AU2016257996A1/en not_active Abandoned
- 2016-05-05 HK HK18109321.1A patent/HK1249920A1/zh active IP Right Revival
- 2016-05-05 TW TW114118710A patent/TW202536180A/zh unknown
- 2016-05-06 UY UY0001040330A patent/UY40330A/es active IP Right Grant
- 2016-05-06 UY UY0001036671A patent/UY36671A/es active IP Right Grant
-
2017
- 2017-11-01 US US15/800,517 patent/US20180100150A1/en not_active Abandoned
-
2019
- 2019-05-24 US US16/421,745 patent/US10934544B2/en active Active
-
2020
- 2020-04-22 JP JP2020075777A patent/JP7530204B2/ja active Active
- 2020-12-15 US US17/121,858 patent/US20210246447A1/en not_active Abandoned
-
2021
- 2021-10-28 AU AU2021258003A patent/AU2021258003A1/en not_active Abandoned
-
2022
- 2022-06-30 JP JP2022106599A patent/JP2022141707A/ja active Pending
-
2023
- 2023-07-05 US US18/218,155 patent/US12338439B2/en active Active
-
2024
- 2024-02-06 AU AU2024200717A patent/AU2024200717B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519797A5 (enExample) | ||
| CN110268060B (zh) | α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法 | |
| CN111343994B (zh) | 用于抑制血管生成素-样3 (ANGPTL3)的表达的RNAi剂和组合物以及使用方法 | |
| JP6234370B2 (ja) | 神経変性障害におけるマイクロｒｎａ | |
| JP5066095B2 (ja) | 染色体ｄｎａに標的化されるオリゴマーによる遺伝子発現の調節 | |
| US20250270555A1 (en) | Organic compositions to treat beta-catenin-related diseases | |
| JP2017532038A5 (enExample) | ||
| RU2014147563A (ru) | КОМПОЗИЦИИ i-PHK ДЛЯ СЕРПИНА C1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| CN102149390A (zh) | 补体拮抗剂及其应用 | |
| JP2016518331A5 (enExample) | ||
| CN108064313A (zh) | 用于抑制因子xii的基因表达的组合物和方法 | |
| JP2018516091A5 (enExample) | ||
| JP2015519047A5 (enExample) | ||
| JP2016506240A5 (enExample) | ||
| RU2014101627A (ru) | КОМПОЗИЦИИ иРНК ДЛЯ СХОДНОГО С АНГИОПОЭТИНОМ 3(ANGPTL3) БЕЛКА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| CN105008533A (zh) | 嵌合单链反义多核苷酸和双链反义试剂 | |
| JP2010532163A5 (enExample) | ||
| JP2009537153A5 (enExample) | ||
| TWI462741B (zh) | 使用微rna 195提供神經保護作用的方法 | |
| EP3665281A1 (en) | CONDITIONAL-siRNAS AND USES THEREOF IN TREATING CARDIAC HYPERTROPHY | |
| JP2017510583A (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JPWO2021195307A5 (enExample) | ||
| JP2020537653A (ja) | アシアロ糖タンパク質受容体１の発現を阻害するためのＲＮＡｉ剤および組成物 | |
| CN104995300A (zh) | Rna活性和血管通透性的调节 | |
| JPWO2021167841A5 (enExample) |